Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Pulmonx Corp Market Cap
From what 6 stock analysts predict, the share price for Pulmonx Corp (LUNG) might increase by 105.17% in the next year. This is based on a 12-month average estimation for LUNG. Price targets go from $10 to $17. The majority of stock analysts believe LUNG is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
LUNG is a stock in Healthcare which has been forecasted to be worth $13.5 as an average. On the higher end, the forecast price is $17 USD by Jason Bednar from Piper Sandler and on the lower end LUNG is forecasted to be $10 by Joanne Wuensch from Citigroup.
These are the latest 20 analyst ratings of LUNG.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Rick Wise Stifel | Buy | $16 | Maintains | Oct 31, 2024 |
| Jon Young Canaccord Genuity | Buy | $16 | Maintains | Aug 1, 2024 |
| Jason Bednar Piper Sandler | Overweight | $12 | Maintains | Aug 1, 2024 |
| Larry Biegelsen Wells Fargo | Equal-Weight | $10 | Maintains | Aug 1, 2024 |
| Frank Takkinen Lake Street | Buy | $12 | Initiates | Jun 4, 2024 |
| Jon Young Canaccord Genuity | Buy | $15 | Maintains | May 2, 2024 |
| Jason Bednar Piper Sandler | Overweight | $17 | Reiterates | Apr 3, 2024 |
| Larry Biegelsen Wells Fargo | Equal-Weight | $14 | Downgrade | Feb 23, 2024 |
| Joanne Wuensch Citigroup | Buy | $17 | Maintains | Feb 23, 2024 |
| Larry Biegelsen Wells Fargo | Overweight | $16 | Maintains | Feb 22, 2024 |
| Rick Wise Stifel | Buy | $17 | Maintains | Feb 22, 2024 |
| Jason Bednar Piper Sandler | Overweight | $17 | Maintains | Feb 22, 2024 |
| Jason Bednar Piper Sandler | Overweight | $13 | Maintains | Oct 31, 2023 |
| William Plovanic Canaccord Genuity | Buy | $12 | Maintains | Oct 31, 2023 |
| Alexander Nowak Craig-Hallum | Buy | $18 | Initiates | Sep 5, 2023 |
Piper Sandler | Overweight | Maintains | Aug 3, 2023 | |
| Joanne Wuensch Citigroup | Buy | $16 | Maintains | Jul 11, 2023 |
| Cecilia Furlong Morgan Stanley | Equal-Weight | $14 | Maintains | May 3, 2023 |
| Jason Bednar Piper Sandler | Overweight | $15 | Maintains | May 3, 2023 |
| Joanne Wuensch Citigroup | Buy | $14 | Maintains | May 3, 2023 |
When did it IPO
2020
Staff Count
279
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Steven S. Williamson
Market Cap
$252.7M
In 2023, LUNG generated $68.7M in revenue, which was a increase of 27.98% from the previous year. This can be seen as a signal that LUNG's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 4, 2024, at 9:30 AM PT.
Why It Matters - Pulmonx's participation in a prominent healthcare conference may signal potential growth and innovation, influencing investor sentiment and stock performance.
Thu, 21 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Pulmonx (LUNG) has a consensus price target suggesting a potential upside of 117.7%. Recent earnings estimate revisions indicate possible near-term stock gains.
Why It Matters - The 117.7% upside potential suggests significant growth opportunity for Pulmonx (LUNG), while rising earnings estimates may indicate positive momentum, attracting investors.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Pulmonx Corporation is expanding its collaboration with the American Lung Association to launch new programs for educating patients and providers about treatments for severe COPD and emphysema.
Why It Matters - Pulmonx's collaboration with the American Lung Association enhances its market position and can boost demand for its treatments, potentially driving revenue growth and investor interest.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Pulmonx Corporation (Nasdaq: LUNG) will participate in a fireside chat at the Stifel 2024 Healthcare Conference on November 19, 2024, at 6:10 AM PT / 9:10 AM ET.
Why It Matters - Pulmonx's participation in the Stifel Healthcare Conference may provide insights into its business strategy and future growth, potentially influencing stock performance and investor sentiment.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Wall Street analysts' price targets suggest a potential upside of 89.6% for Pulmonx (LUNG), supported by positive earnings estimate revisions.
Why It Matters - The 89.6% upside potential in Pulmonx (LUNG) suggests strong growth expectations, and positive earnings revisions indicate improving fundamentals, which may attract investor interest.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Pulmonx Corporation (LUNG) held its Q3 2024 earnings call, discussing financial results and business updates. Details on revenue and guidance are available in the transcript.
Why It Matters - Pulmonx Corporation's Q3 2024 earnings call provides insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
